Amgen Inc. (NASDAQ:AMGN) Shares Bought by EP Wealth Advisors LLC

EP Wealth Advisors LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 10.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,852 shares of the medical research company’s stock after purchasing an additional 3,024 shares during the period. EP Wealth Advisors LLC’s holdings in Amgen were worth $10,585,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Capital Performance Advisors LLP purchased a new stake in shares of Amgen during the third quarter worth about $25,000. Strategic Financial Concepts LLC purchased a new stake in Amgen during the 2nd quarter worth approximately $26,000. Hershey Financial Advisers LLC acquired a new position in Amgen during the 2nd quarter valued at approximately $30,000. nVerses Capital LLC purchased a new position in shares of Amgen in the second quarter worth $31,000. Finally, Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen during the second quarter worth $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of several research reports. Truist Financial downgraded Amgen from a “buy” rating to a “hold” rating and upped their target price for the company from $320.00 to $333.00 in a research report on Monday, October 14th. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Citigroup decreased their target price on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 28th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $323.05.

Amgen Stock Down 0.6 %

AMGN stock opened at $272.58 on Friday. Amgen Inc. has a 52 week low of $257.80 and a 52 week high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a 50-day simple moving average of $306.58 and a 200-day simple moving average of $315.82. The stock has a market capitalization of $146.52 billion, a P/E ratio of 34.90, a P/E/G ratio of 3.08 and a beta of 0.55.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the prior year, the firm earned $4.96 earnings per share. The business’s revenue was up 23.2% compared to the same quarter last year. Equities analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.30%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.